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Figure 1.2 Apoptosis pathways leading from activation of the BCR.  Cross-linking of the BCR 
on  the  surface of B  cells  in  response  to  Ag  leads  to  the  activation  of downstream  molecules. 
Activation of these molecules can either lead to cell death or cell survival depending on the type of 
PTKs activated.  The difference in  the type of pro- or anti-apoptotic factors depends on the stage of 
B cell development and the severity of the PTK activated. 
6 normal splice sites are altered by mutations(146),  Once the correct exons are recognised by 
the  splicesome,  the  flanking  splice  sites  must be joined in  the  correct  5' to  3'  order to 
prevent exons being missed out of  the completed sequence(l49), 
Alternative splicing appears to be a tightly regulated process in a cell type or developmental 
stage specific manner(l50),  Uncontrolled splicing can have disastrous effects, 15% of  human 
genetic diseases are caused by mutations that destroy functional splice sites or generate new 
ones(l50,  151),  Although splicing of eukaryotic  genes  is  well understood,  explaining why 
specific splice sites are selected for splicing has proven difficult. 
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Figure 3.6 Effect of increasing concentrations of anti-Fcll- mAb on EHRB 
BCR  induced  apoptosis.  2x 105  EHRB  cells  were  treated  with  either  control 
(CP  1117) or anti-Fcll (M 15/8) mAb at various concentrations for 24 hours at 37°C  in  a 
humidified  incubator.  Levels of cellular apoptosis were analysed  by  flow  cytometry 
using  either  AnnexinV  PI  (a)  or  DioC6  (b)  staining.  Mean  values  ±  SD  of three 
independent experiments. 
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Figure 3.8 Apoptosis induced by antibodies recognising different regions of 
mlgM on EHRB cells.  2x  105  EHRB cells were treated with various Ab (I 0  ~Lg/ ml) 
directed  at  different  domains  of mIgM  for  24  hours  at  37oC.  Levels  of cellular 
apoptosis  were  measured  using  FITC  labeled  annexin  V  and  PI  by  flow  cytometry. 
Mean values ±  SD given for three  independent experiments.  Antibodies  used  were: 
control (CPI/17), anti-Fd~ (XG9), anti-A (Mc24IC6), anti-Fc~ (MIS/8), and polyclonal 
anti-~ Ab. 
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Figure 3.9  Effect of mAb directed to  similar domains of mlgM on  BCR 
induced cellular apoptosis. 1  xl 05  EHRB cells were treated with various mAb (10 
Ilg/ml) for 24 hours at 37oC.  The level ofBCR induced apoptosis was analysed by flow 
cytometry  with  FITC  labeled  AnnexinV  and  PI.  Mean  values  ±  SD  of three 
independent experiments.  Cells treated with the following Ab; Control (CP 1  / 17), anti-
FCIl  (MI5/8,  ZL7/5  and  Mc244Gl0),  anti-Fdll  (MA5,  XG9,  and  M2E6),  anti-A 
(Mc24IC6 and M 15/2) and polyclonal anti-~l Ab. 
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Figure 3.15  Syk activation  in  EHRB  cells  stimulated with  different anti-BCR 
mAh.  4x 106  EHRB cells were stimulated with various mAb (I 0  ~g/ml) for five minutes at 
37oC.  Cells were then  lysed  and  proteins containing phosphorylated tyrosine residues  were 
immunoprecipitated  by  incubating  overnight  at  40C  with  4G I 0  mAb  (2  ~Lg)  followed  by 
protein G bound to sephrose beads for two hours at 4oC.  Immunoprecipitates were resolved 
on  12.5% SDS-PAGE gels, transferred to  PVDF membrane and immunoblotted for activated 
Syk (a).  Samples of cell  Iysates were used as controls for the total  level of Syk (b).  Cells 
were treated  with  the following  mAb:  Irr (CPI1I7);  Fc~ (M 15/8);  CD79a (ZL7/4); CD79b 
(AT 105/1);  Fd~ (XG9);  and  Poly  (polyclonal  anti-~ Ab).  Representative of at  least  three 
separate experiments. 
65 As differences in signalling appear to be linked to  the induction of apoptosis, it was also of 
interest to detennine the nature of the BCR complex bound by the panel of anti-BCR mAb. 
Research  has  shown  that  the  BCR  from  anergic  B  cells  is  disrupted,  with  the  CD79 
heterodimer not associated with mlgM(180,  181).  Therefore,  it  is  possible that certain anti-
BCR  cause  a  disruption  to  the  BCR  structure,  preventing  complete  activation  of the 
intracellular signalling cascade, leading to the induction of apoptosis.  For these reasons, in 
this chapter the nature of the BCR complex was assessed before and after binding with our 
panel of anti-BCR mAb.  In addition,  the hypothesis  that the  varying levels  of apoptosis 
induced by the  different mAb might be explained by variable redistribution of the  BCR 
components into lipid rafts was explored. 
79 Prior to  performing these experiments, we needed to  optimise the BN  -PAGE method,  to 
refine both the concentration and type of markers to use and to determine the volume of cell 
lysate  that  could  be  resolved  using  these  gels  (Figure  4.20a).  Following  extensive 
preliminary experimentation, Amersham Native markers along with ferritin  at  2.5  mg/ml 
appeared to be the best, allowing identification of large complexes up to 880kD and smaller 
complexes down to 66kD.  In order to obtain the maximum capacity of the BN-PAGE gels 
for resolving the cell lysates, increasing concentrations of EHRB cells were lysed in  BN-
P  AGE lysis buffer and separated.  Figure 4.20b, shows that the gel  system could resolve 
lysates from up to  8x 1  0
6  cells and therefore, should be adequate to resolve the amount of 
protein loaded using our method. 
Another  problem we  predicted  was  the  release  of immunoprecipitated  complexes  from 
protein A.  When resolving immunoprecipitated protein through SDS-PAGE, samples are 
denatured in  SDS  loading buffer,  releasing bound protein from  protein  A  coated beads. 
However, when using BN-P  AGE,  samples cannot be denatured as  this would lead to  the 
break up  of immunoprecipitated protein complexes.  Therefore, further experiments were 
carried out to  determine the best method to  allow disassociation of the bound mAb from 
protein A.  Figure 4.21 a shows that a tris-glycine elution buffer with a pH of pH2.5  gave 
optimal  elution  of bound  mAb.  However,  since  it  was  thought  that  at  this  low  pH, 
disruption of the BCR complex would occur, a tris-glycine buffer with pH4.5 was chosen 
for the experiments as this was still able to elute the majority of  the mAb. 
To see if  our method worked, we treated 4xl0
6 EHRB cells with irrelevant control, anti-Fql 
or anti-Fdll mAb for 30 minutes on ice.  Samples were then washed twice in PBS  before 
being lysed in 1  % digitonin BN-PAGE lysis buffer.  Supernatants were incubated over night 
with protein A coupled to sephrose and samples were then washed four times in lysis buffer 
before  the  addition  of 20  III  of 0.1  M  tris-glycine  elution  buffer  and  incubated  for  30 
minutes at room temperature.  Samples were then resolved through 16 to 5.5% gradient BN-
P  AGE gels,  protein transferred to  PVDF membrane and immunoblotted for  mIgM using 
HRP-labelled anti-Il Ab.  Figure 4.21 b shows that pH4.5 elution buffer allows disassociation 
ofBCR complexes from protein A coated sepharose beads.  Samples eluted using the pH2.5 
elution buffer showed increased levels of eluted mIgM, which appeared to  smear through 
the upper section of  the gels, whereas the pH7.0 elution buffer eluted very little of  the bound 
mIgM.  For these reasons, in subsequent BN PAGE experiments, 4x 1  0
6 cells were lysed per 
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Figure 4.21  Comparison of elution of BCRImAb complexes from protein A 
beads using various pH buffers.  (a)  Anti- ~L mAb M 15/8 (1.6 mg/ml) was  loaded 
onto a  Seph4B  protein  A  column  (10  mg/ml),  and  then  bound  mAb was eluted  using 
various 0.1  M tris-glycine buffer of various pH.  (b) 4x  106  EHRB cells were treated with 
various anti-BCR mAb for 30 minutes on ice prior to lysis using  1  % digitonin and BCR 
complexes were immunoprecipitated overnight using protein A coated beads.  Protein A 
beads were then washed  four times with ice cold  lysis buffer, and incubated with 20  III 
0.1  M  tirs-glycine  buffer  at  various  pH  (2.5,  4.5  or  7.0),  for  30  minutes  at  room 
temperature.  Protein  A beads were then pulse spun, and  10  III supernatant separated on 
BN-PAGE gels,  and immunoblotted for  presence of mIgM  as detailed  in  Figure 4.16. 
Cells  were treated  with the  following mAb;  Irr  is  CP 1117,  FCIl  is  M 15/8,  and  Fdll  is 
XG9.  Representative of  at least three independent experiments. 
111 this  area of the lipid raft assay contains the lipid insoluble fractions.  The mIgM of cells 
treated with the anti-Fdll mAb failed to  translocate IgM into the lipid insoluble fractions. 
Interestingly, CD79b did not translocate into lipid insoluble fractions from cells stimulated 
with either the anti-Fcll or polyc1onal Ab, although IgM translocated with both treatments. 
A  more  rapid,  refined  method  used  for  investigating  movement  of proteins  into  lipid 
insoluble fractions was also employed as  described by(153).  This method involves lysis of 
treated cells with 1  % TX-I00 lysis buffer and separation into pellet and lysate fractions by 
centrifugation  at  16,OOOg  for  15  minutes  at  4°C.  EHRB  cells  were  treated  with  either 
control,  anti-Fcll,  anti-Fdll and as  a positive control for  raft redistribution, the  anti-CD20 
mAb  Rituximab.  Following  treatment,  lysis  and  separation,  supernatant  from  treated 
samples was removed and the soluble and insoluble fractions were resolved by SDS-PAGE, 
transferred to PVDF membrane and probed for the BCR using anti-Il or anti-CD79b Ab.  As 
a method and loading control, blots were re-probed for P AG, CD20 and ~-actin.  These data 
demonstrate  that,  as  expected,  P AG  was  present  only  in  the  insoluble  pellet  fraction. 
Similarly,  CD20  was  shown  to  be  redistributed  into  the  insoluble  fraction  following 
Rituximab  treatment.  Thus  such,  these  data  validate  the  technique  for  detecting 
redistribution events.  Regarding BCR redistribution, Figure 4.26a shows that cells treated 
with the anti-Fcll mAb showed increased amounts of mIgM in the insoluble/pellet fraction 
compared to cells treated with the anti-Fdll mAb.  Again, CD79b did not translocate into the 
insoluble  fraction  of cells  treated  with the  anti-Fcll  mAb.  In  fact,  the  level  of CD79b 
present in the insoluble fraction did not change regardless of  which mAb was used to cross-
link the BCR.  Subsequently, the experiment was repeated several times and the amount of 
IgM and CD79b in the pellet or lysate fraction was quantitated using densitometry. These 
data are shown in Figure 4.26b, and demonstrate that about 20% of IgM was moved into the 
pellet fraction when cells were treated with the anti-Fcll mAb,  compared to  cells treated 
with the other mAb, where the amount of IgM present in the pellet fraction did not change 
when compared to cells treated with the irrelevant control mAb. 
118 modulation.  However,  although  a  large proportion of mIgM was modulated when cells 
were treated with the anti-Fcll mAb, the rate of mIgM modulation was not different from 
cells  treated  with  the  other  anti-IgM  mAb.  Monoclonal  Ab  directed  at  the  CD79 
heterodimer had little effect on the amount of  mIgM or CD79 modulated over short periods 
of time.  However, a combination of both anti-CD79a and CD79b mAb led to an increased 
rate of mIgM modulation.  These results suggest that the rate of mIgM modulation has little 
effect on the ability of  anti-BCR mAb to induce apoptosis. 
Next,  we decided to  investigate the modulation rate of the  CD79 heterodimer on EHRB 
cells.  Cells treated with the anti-Fcll mAb showed a reduction in the amount of CD79a and 
CD79b  modulated,  compared  to  cells  treated  with  anti-Fdll  or  anti-A  light  chain  mAb. 
Therefore,  it  appears that although the  anti-Fcll mAb induces rapid modulation of bound 
mIgM from the cell surface, a proportion of the CD79 heterodimer may remain.  In EHRB 
cells  stimulated  with  anti-BCR  mAb  that  induce  apoptosis,  the  mIgM  appears  to  also 
dissociate from the CD79 heterodimer.  Previous studies have shown that mIgM of anergic 
B  cells  physically  dissociate  from  the  CD79  heterodimer,  preventing  generation  of 
intracellular signals upon binding of antigen(l80, 181).  However, as  discussed in the previous 
chapter, cells treated with the anti-BCR mAb that induce apoptosis continue to signal for up 
to  1  hour  following  treatment  with mAb.  As  mIgM  may disassociate  from  the  CD79 
heterodimer, it is  likely that mIgM is modulated leaving the CD79 heterodimer at  the cell 
surface in contact with PTK.  As the CD79 heterodimer is  not internalised, the signalling 
cascade is not shut down, leading to prolonged signalling and apoptosis. 
To  confirm  that  the  anti-Fcll  mAb  causes  disassociation  of  mIgM  from  the  CD79 
heterodimer, we devised a method that would allow immunoprecipitation of anti-BCR mAb 
along  with  bound  BCR complexes.  Cells  were  lysed  with  1  %  digitonin  lysis  buffer. 
Digitonin allows whole BCR complexes to be isolated from the cell without disruption of 
the complete BCR complex(I09)., 
An interesting  observation  from  the  immunoprecipitation  experiments  was  that  different 
anti-BCR mAb bound to  the cell surface immunoprecipitated different amounts of mIgM. 
Interestingly,  complete BCR complexes were not  immunoprecipitated when EHRB  cells 
were treated with the anti-Fcll mAb as  large amounts of mIgM were immunoprecipitated 
that were not associated with CD79b.  We knew that when the anti-Fcll mAb was added to 
celllysates whole BCR complexes could be immunoprecipitated, shown by the presence of 
121 19M  and CD79b and therefore this defect was not due to  an inability of the mAb to  IP  the 
whole BCR per se.  As expected, the other anti-BCR mAb raised against the m1gM domain 
of the BCR bound the whole BCR complex, but the amount of mIgM immunoprecipitated 
was smaller than the amount immunoprecipitated with the anti-FcJ.! mAb.  When developing 
this immunoprecipitation method, differences in the amount of CD79b immunoprecipitated 
with mIgM were observed,  depending on the number of times the Sepharose beads were 
washed in cold lysis buffer.  This could be due to  either free CD79b protein binding to  the 
Sepharose beads,  or the  disruption of the  BCR complex  as  CD79b is  ionically bound  to 
mIgM.  Therefore, this method,  although giving good preliminary data needs to  be  more 
thoroughly investigated for future use. 
This phenomenon clearly acted independently of cellular mechanisms.  Inhibition of cellular 
metabolic  activity  with  specific  inhibitors,  or  binding  anti-BCR  mAb  on  ice  without 
warming  the  cells  to  37°C,  fails  to  prevent  immunoprecipitation  of these  large  m1gM 
complexes  immunoprecipitated  with  the  anti-FcJ.!  mAb.  This  suggests  that  these  large 
immunoprecipitated mIgM complexes could be caused directly by binding of the mAb  to 
the BCR, and not due to a cellular response. 
Together, these results suggest that the  anti-FdJ.!,  A,  or Id mAb immunoprecipitated single 
complete BCR complexes.  This is  due to  the fact that these mAb immunoprecipitated less 
mIgM,  probably because  they bind  monogamously to  the  BCR,  with one  Ab  molecule 
binding to  one mIgM molecule.  Anti-FcJ.! mAb that could bind bigamously between BCR 
complexes, immunoprecipitated more mIgM,  as  one Ab  molecule can bind to  two  m1gM 
molecules.  To  help prove this theory,  EHRB cells were incubated with concentrations of 
mAb  that  gave  equal  levels  of  bound  mAb.  However,  the  anti-FcJ.!  mAb  still 
immunoprecipitated more mIgM compared to the other anti-BCR mAb, even when the same 
amount ofmAb was bound at the cell surface as the other anti-BCR mAb. 
Another theory for the large amounts of mIgM immunoprecipitated with anti-FcJ.! mAb was 
that free  mAb that had not bound to surface mIgM was available to  bind to  cytosolic 19M 
when the cells were lysed, prior to immunoprecipitation.  To address this question, EHRB 
cells  were  surface  radio-labelled  with  1
125  and  BCR  complexes  immunoprecipitated 
following  binding of mAb  to  surface BCR,  or  addition of mAb  to  cell  lysates.  Results 
showed that  the  level of surface mIgM  immunoprecipitated with the  anti-FcJ.!  mAb  was 
greater than  that  observed when cells  were  treated with the other anti-BCR mAb.  Cell 
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Figure 5.5 Effect of titrating anti-Jl  concentration on BCR induced apoptosis on 
WEHI-231 cell lines.  (a) I x 105  WEHI-23 I cells were treated with either control (KT3) or 
anti-fl  (Mc39-12)  at  I 0  ~lg/m l  for  24  or 48  hours,  at  370C  and  levels  of BCR  induced 
apoptosis assessed by flow cytometry using annexin V/PI  (b) lxl05 WEHI-23 I cells were 
treated with various concentrations of either control (KT3) or anti -~  (Mc39-12) mAb for 48 
hours  at  37oC.  Levels  of apoptosis  were  assessed  using  annexin  V/PI  staining  by  flow 
cytometry.  Results shown are mean values ± SO from three separate experiments. 
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Figure 5.10 Surface expression of full  length mCD79b and mACD79b in  pCI-
puromycin vectors on 293T cells.  293T cells were transfected with  I flg  mCD79b full, 
I  flg  m~CD79b pCI-puromycin, or I  flg  empty pCI-puromycin vector (Figure S.9a). 293T 
cells were also transfected with the above constructs in  the presence of either I flg  mCD79a 
pCI-puromycin vector (Figure S.9b).  Levels of mCD79b expressed at the plasma membrane 
were assessed using FITC labelled anti-CD79b (HM79-1 I) by flow cytometry 24 hours post 
transfection.  Levels of  expression are from gated viable cells, and a representative of  at least 
three independent experiments. 
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10' Samples were then lysed, and protein separated on 12.5% SDS-PAGE gels, and transfened 
to  PVDF membranes.  Membranes were then probed for the presence of active p38  (anti-
active  p38  1  :2500)  or  active  ERK  (anti-active  MAPK  1  :5000).  As  a  loading  control 
membranes  were re-probed  for  the  presence  of p-actin  (p38)  or total  ERK (active  ERK 
blots). 
Figure  5.15a  shows  that  between  cell  lines  there  is  no  difference  in  the  level  of p38 
activation.  Western blots were subjected to densitomtry and mean values ± SD were plotted 
for three independent experiments (Figure 5.15b).  Maximum levels ofp38 activation were 
then calculated as  detailed in section 3.2.11  (Figure 5  .15c).  Results show that there is  no 
difference in the levels of p38  activation between the cell lines.  The maximum levels of 
activated p38 were observed after 5 minutes of  stimulation and then decreased. 
Figure 5.16a, shows the levels of  ERK activation between the two cell lines.  Again western 
blots  were  subjected  to  densitometry  and  mean  values  ±  SD  from  three  independent 
experiments  were  plotted  (Figure  5  .16b),  and  calculated  as  percentages  of maximum 
activation  of ERK (Figure  5.16c).  The  first  observation  was  that  in  both,  only  ERK2 
appeared to be activated upon cross-linking mIgM with the anti-Il mAb, compared to  cells 
treated  with  the  control  mAb.  When  immunoblots  were  re-probed  for  total  ERK,  all 
samples  showed  equal  levels  of both  ERK1  and  ERK2  (Figure  5.16a).  Therefore, 
intracellular signals  generated by anti-Il mAb cross-linking mIgM appear to  only activate 
ERK2 and not ERKl.  Early kinetics between wild type and clone 6.35  WEHI-231  cell lines 
show similar levels of ERK2 activation, with lower levels of activation observed following 
stimulation for 1 minute (Figure 5  .16b).  Maximum levels of ERK activation were observed 
following stimulation for 5 minutes in both cell lines, and then decreased over time (Figure 
5  .16c).  However, levels of activated ERK2 fall  at a faster rate in the wild type WEHI  -231 
cells  compared  to  the  6.35  WEHI-231  cells,  where  activated  ERK2  was  still  observed 
following stimulation for 60 minutes. 
149 pCIpuro vectors encoding mCD79b.  Furthennore, as the cytoplasmic domain is present in 
the alternative transcript, the mAb should also recognise  m~CD79b if it is expressed as  a 
stable  protein.  Western  blot  analysis  of lysates  from  COS-7  cells  transfected  with 
m~CD79b  in the pCI-puromycin expression vectors indicated that the alternative transcript 
is  indeed capable of encoding for a mature, stable protein as  both the mAb HM79-11  and 
AT1 0712  could recognise it  when over-expressed in  COS-7  cell  lines.  Furthennore,  the 
amount  of full  length  and  alternative  protein  detected  appeared  equivalent,  possibly 
indicating that both full  length and alternative transcripts have similar stability.  The fact 
that the HM9-11  mAb was able to  detect the alternative transcript indicates that this Ab  is 
directed to the short peptide sequence encoded by exon 2 present in both full and truncated 
proteins, similar to the observation the mAb directed to  human CD79b proteins recognise 
this region. 
To  confinn that endogenous levels of m~CD79b are  detectable  in  B cells,  i.e.  when not 
over-expressed in a non-B cell line, we analysed the protein expression of m~CD79b in  a 
selection of mouse B  cell  lines,  and  show that the  m~CD79b protein could be  detected. 
Furthennore, its expression correlated with the level of mRNA produced, in that WEHI-231 
murine B cell lines expressed the lowest level compared to A20 and nBCLI  cells. 
Signalling through the BCR is pivotal during B cell deve10pment(2,  187).  Signalling from  a 
pre-BCR in  the  absence  of an  external  ligand  generates  intracellular signals  required  to 
allow cellular proliferation, rearrangement of mIg light chain, and differentiation(87, 100).  In 
the absence of BCR signalling, pre-B cells die.  However, at the immature stage of B cell 
development cross-linking the BCR generates intracellular signals that induce programmed 
cell death, apoptosis, preventing fonnation of self reactive B cells(187).  Although the fate of 
B cells  at  different stages of development are  quite different, they are  all  generated  from 
intracellular signals initiated from the BCR, in particular the CD79 heterodimer(4, 18). 
At  all  stages  of development it  is  thought that B  cells contain the  same basic  signalling 
molecules,  what  has  still  to  be  shown  are  specific  differences  in  signalling  pathways 
between B cells at these different stages of development.  In this study the WEHI-231  cell 
line, used extensively as  a model of immature B cells(184, 185) expressed relatively low levels 
of  m~CD79b  at both the mRNA and protein level but, was most sensitive to  BCR induced 
apoptosis upon cross-linking the BCR, with as  little as  1 J.lg/ml  of the anti-J.l  mAb giving 
effective cross-linking.  In contrast, A20 B cells, used as  a mature B cell model(l88) express 
153 we  investigated  the  cellular  localisation  of mllCD79b,  and  assessed  whether  it  could 
interfere with PTKs activated near to the plasma membrane upon BCR cross-linking. 
The cellular localisation of mllCD79b in cell lines was initially assessed by tagging a YFP 
reporter molecule to the N-terminal domain of both full length and mllCD79b.  mllCD79b 
appears to  be expressed within the cell,  near to  the surface in both transiently transfected 
293T cells  and stably transfected WEHI-231  cells.  These results  indicated that llCD79b 
could be expressed near to  the plasma membrane of B  cells, allowing close proximity to 
essential PTKs utilised by cross-linked BCR.  However, as with flouresent microscopy the 
exact  location  of mllCD79b  cannot  be  assured  and  so  this  method  only  gives  an 
approximate cellular location of  the protein.  We then used mAb directed at the extracellular 
domain  of mCD79b  to  assess  whether the  proteins  were  actually  expressed  at  the  cell 
surface.  We showed previously that the mAb raised  against the  extracellular domain  of 
mCD79b  (HM79-11)  can  recognise  both  the  full  length  and  mllCD79b  proteins. 
Interestingly, we were able to detect low levels of full length mCD79b at the cell surface of 
transfected 293T cells, which was enhanced when cells were co-transfected with mCD79a 
allowing the formation of  a stable heterodimer, and increased expression at the cell surface. 
However,  we  were  unable  to  detect  expression  of mllCD79b  either  in  the  presence  or 
absence of CD79a.  These data appear to indicate that mllCD79b is not expressed at the cell 
surface.  However, we reasoned that although the mAb may be capable of binding to  the 
short peptide encoded by exon two of  mllCD79b, it may be impaired in this context when in 
close proximity to the plasma membrane.  To test if  this was the case we decided to create a 
fusion protein that contained domains three and four of rat CD4 tethered to  the N-tenninus 
of mllCD79b  (rCD4d3+4).  The  theory  was  that  this  should  create  a  spacer  region 
presenting the  short peptide region of mllCD79b away from  the plasma membrane,  thus 
allowing binding without interference from the close proximity of  the plasma membrane. 
293T  cells  were  transfected  with  both  full  length  (rCDd3+4-mCD79b)  and  mllCD79b 
(rCD4d3+4-mllCD79b) fusion proteins with or without mCD79a, and  surface  expression 
assessed using anti-mCD79b (HM79-11) or anti-rCD4 (OX68) mAb.  As shown previously, 
the anti-mCD79b mAb could only recognise full-length mCD79b and not mllCD79b.  The 
surface expression of full-length mCD79b was once again enhanced when 293T cells were 
co-transfected  with  mCD79a.  It  was  no  surprise  that  anti-rCD4  mAb  recognised 
rCD4d3+4-mCD79b expressed at the cell surface.  However, mllCD79b was also detected 
156 Finally to understand the functional role of m,6.CD79b during B cell development it would 
be of interest to produce a transgenic murine model that over-expresses m,6.CD79b,  and to 
observe what the over-expression of m,6.CD79b  may have on B  cell development.  If the 
expression of m,6.CD79b could be controlled by utilising a Cre-Lox system, then the effect 
of over-expressing m,6.CD79b could be observed at different stages of B cell development 
ex-vivo.  The effect of overexpresing m,6.CD79b in murine B cells could be investigated at 
the protein level, by looking at PTK affected, and at the genetic level as described above. 
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